<DOC>
	<DOCNO>NCT02814955</DOCNO>
	<brief_summary>Atrial fibrillation ( AF ) common cardiac arrhythmia constantly grow prevalence AF . The purpose paroxysmal AF processing control outbreaks pulmonary vein , medicate way ( antiarrhythmic ) interventional . Ablation ( radiofrequency cryotherapy ) become context recognized effective treatment AF . In addition , antithrombotic treatment context major treatment prevention stroke ( stroke ) . They often associate antiarrhythmic treatment prevent recurrence AF slow relapse . Recent experimental study highlight direct electrophysiological property dabigatran rivaroxaban pulmonary vein leave atrium . Dabigatran demonstrate study induced prolongation potential action pulmonary vein leave atrium decrease incidence FA-induced stimulation . Conversely , rivaroxaban induces shorten action potential leave atrium ( untested property pulmonary vein ) . To knowledge , apixaban warfarin study context . It therefore possible new oral anticoagulant ( NACOS ) AVK ( fluindione warfarin ) , direct electrophysiological effect pulmonary vein leave atrium could influence AF recurrence ( effect `` antiarrhythmic-like `` rather pro-arrhythmic effect ) ablation.A retrospective analysis conduct University Hospital Caen low number suggest patient dabigatran would less pulmonary vein connect early ablation procedure patient warfarin rivaroxaban . Despite limitation inherent analysis ( low number , retrospective analysis , unique set studied limit ) , result consistent fundamental study , thus encourage u pursue hypothesis obtain statistical power reliability measurement result . We therefore propose study electrophysiological effect NACOS ( apixaban , dabigatran , rivaroxaban ) warfarin ( warfarin fluindione ) pulmonary vein leave atrium patient refer ablation paroxysmal AF ( radiofrequency cryotherapy ) CHU Caen Tours clinic Saint Martin Caen .</brief_summary>
	<brief_title>Electrophysiological Effects NACOS AVK Pulmonary Veins Left Atrium Paroxysmal AF Catheter Ablation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>All hospitalize patient ablation paroxysmal AF On healthy heart Sinus rhythm procedure Patient &gt; 18 year Patient &lt; 18 year Severe Mitral valve disease , underlie heart disease Patients refuse participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>pulmonary vein</keyword>
	<keyword>oral anticoagulant</keyword>
	<keyword>electrophysiology</keyword>
	<keyword>anticoagulant drug</keyword>
</DOC>